Spruce Street Capital LP
In its 13F for Q4 2025 (holdings as of December 31, 2025, filed February 13, 2026), Spruce Street Capital LP reported 27 stock positions worth $302.7 million. Its top holding was Cidara Therapeutics (CDTX) at 17.0% of the portfolio, followed by Relay Therapeutics (RLAY, 8.3%) and LB Pharmaceuticals (LBRX, 7.4%).
- Most Recent 13F
- Q2 2026
- Location
- NEW YORK, NY
- CIK
- 0002050194
- Portfolio Value
- $302.7M (Q4 2025)
- SEC Filing
- 0002050194-26-000001 ↗ filed Feb 13, 2026
Holdings Value
Holdings 27 stocks · $302.7M
| CDTX Cidara Therapeutics Inc. | 16.95% | 232,269 | $51.3M | — |
| RLAY Relay Therapeutics Inc. | 8.34% | 2,984,125 | $25.2M | — |
| LBRX LB Pharmaceuticals Inc. | 7.40% | 1,005,593 | $22.4M | — |
| RLMD Relmada Therapeutics Inc. | 6.52% | 4,086,181 | $19.7M | — |
| PCVX Vaxcyte Inc. | 6.10% | 400,360 | $18.5M | — |
| KNSA Kiniksa Pharmaceuticals Inte | 5.93% | 434,982 | $17.9M | — |
| EYPT Eyepoint Inc. | 5.93% | 981,543 | $17.9M | — |
| SVRA Savara Inc. | 4.80% | 2,411,093 | $14.5M | — |
| ERAS Erasca Inc. | 4.78% | 3,889,632 | $14.5M | — |
| DNTH Dianthus Therapeutics Inc. | 4.05% | 297,437 | $12.3M | — |
| SRZN Surrozen Inc. | 3.23% | 432,040 | $9.8M | — |
| OCUL Ocular Therapeutix Inc. | 3.14% | 783,999 | $9.5M | — |
| SABS Sab Biotherapeutics Inc. | 2.72% | 2,198,502 | $8.2M | — |
| IKT Inhibikase Therapeutics Inc. | 2.43% | 3,581,603 | $7.3M | — |
| ELVN Enliven Therapeutics Inc. | 2.27% | 446,084 | $6.9M | — |
| NERV Minerva Neurosciences Inc. | 2.20% | 1,655,500 | $6.7M | — |
| ABVX Abivax SA-ADR | 2.19% | 49,119 | $6.6M | — |
| HELP Cybin Inc. | 2.08% | 770,000 | $6.3M | — |
| KALV Kalvista Pharmaceuticals Inc. | 2.07% | 387,968 | $6.3M | — |
| ENTA Enanta Pharmaceuticals Inc. | 2.03% | 389,687 | $6.1M | — |
| ANRO Alto Neuroscience Inc. | 1.31% | 222,844 | $4.0M | — |
| LONA Leonabio Inc. filed as ATHIRA PHARMA INC | 0.98% | 393,701 | $3.0M | — |
| CNTA Centessa Pharmaceuticals Ltd. | 0.64% | 77,997 | $2.0M | — |
| ALEC Alector Inc. | 0.58% | 1,117,986 | $1.7M | — |
| LXEO Lexeo Therapeutics Inc. | 0.57% | 175,000 | $1.7M | — |
| IPSC Century Therapeutics Inc. | 0.47% | 1,421,532 | $1.4M | — |
| STRO Sutro Biopharma Inc. | 0.29% | 75,594 | $875K | — |
Portfolio Sells Q4 2025
No earlier filing to compare with.
Portfolio Buys Q4 2025
No earlier filing to compare with.